Value of the critical flicker frequency in patients with minimal hepatic encephalopathy

Manuel Romero-Gómez1, Juan Córdoba, Rodrigo Jover

  • 1Unit for the Clinical Management of Digestive Diseases, Hospital Universitario de Valme, Sevilla, Spain. mromerog@supercable.es

Abstract

Insights

Critical flicker frequency (CFF) is a simple and accurate tool for diagnosing minimal hepatic encephalopathy (MHE). This test can also predict the development of overt hepatic encephalopathy (HE) in patients with cirrhosis.

Area of Science:

  • Hepatology
  • Neuroscience
  • Clinical Diagnostics

Background:

  • Minimal hepatic encephalopathy (MHE) impacts patients with cirrhosis, but current diagnostic psychometric hepatic encephalopathy scores (PHES) are not widely used in clinical practice.
  • Accurate and accessible diagnostic tools are needed to identify MHE and predict its progression.

Purpose of the Study:

  • To evaluate the utility of critical flicker frequency (CFF) for diagnosing MHE in patients with cirrhosis.
  • To assess CFF's ability to predict the development of overt hepatic encephalopathy (HE).

Main Methods:

  • 114 patients with cirrhosis and 103 healthy controls underwent CFF and PHES testing.
  • MHE was diagnosed using PHES < -4. Patients were followed for 1 year to monitor for overt HE.
  • Correlation and regression analyses were used to assess CFF's diagnostic and predictive capabilities.

Main Results:

  • Mean CFF was significantly lower in patients with MHE compared to non-MHE patients and controls.
  • CFF showed a significant correlation with PHES (r = 0.54, P < 0.001).
  • CFF < 38 Hz predicted the development of overt HE (log-rank: 14.2; P < 0.001) and was independently associated with overt HE development when combined with Child-Pugh score.

Conclusions:

  • CFF is a simple, reliable, and accurate method for diagnosing MHE.
  • CFF is not influenced by age or education, making it a practical diagnostic tool.
  • CFF can predict the future development of overt HE in patients with cirrhosis.

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...